ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
出版年份 2012 全文链接
标题
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue 10, Pages 2479-2516
出版商
Oxford University Press (OUP)
发表日期
2012-09-26
DOI
10.1093/annonc/mds236
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Correlation of tumour BRAF mutations andMLH1methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification
- (2012) Michael T Parsons et al. JOURNAL OF MEDICAL GENETICS
- Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer
- (2012) Hanna K. Sanoff et al. JNCI-Journal of the National Cancer Institute
- Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
- (2012) Ralf-Dieter Hofheinz et al. LANCET ONCOLOGY
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
- (2012) Claus Rödel et al. LANCET ONCOLOGY
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
- (2012) E. Diaz-Rubio et al. ONCOLOGIST
- European cancer mortality predictions for the year 2011
- (2011) M. Malvezzi et al. ANNALS OF ONCOLOGY
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
- (2011) R. Wong et al. ANNALS OF ONCOLOGY
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Diffusion-Weighted MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer: A Multicenter Study
- (2011) Doenja M. J. Lambregts et al. ANNALS OF SURGICAL ONCOLOGY
- Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
- (2011) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?
- (2011) Sébastien Gaujoux et al. DIGESTIVE SURGERY
- Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer
- (2011) James J. Biagi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
- (2011) Erin S. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803
- (2011) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials
- (2011) Vincenzo Valentini et al. JOURNAL OF CLINICAL ONCOLOGY
- Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer
- (2011) Monique Maas et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Mesorectal Fascia Instead of Circumferential Resection Margin in Preoperative Staging of Rectal Cancer
- (2011) Bengt Glimelius et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
- (2011) Carlo Aschele et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Do we need oncology trials tailored for the elderly or frail?
- (2011) Hans-Joachim Schmoll LANCET
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
- (2011) Matthew T Seymour et al. LANCET
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
- (2011) John Burn et al. LANCET
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Has the new TNM classification for colorectal cancer improved care?
- (2011) Iris D. Nagtegaal et al. Nature Reviews Clinical Oncology
- Rectal Cancer: Assessment of Complete Response to Preoperative Combined Radiation Therapy with Chemotherapy—Conventional MR Volumetry versus Diffusion-weighted MR Imaging
- (2011) Luís Curvo-Semedo et al. RADIOLOGY
- Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
- (2010) Vishal Ranpura et al. ACTA ONCOLOGICA
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- Adjuvant chemotherapy in rectal cancer--an issue or a nonissue?
- (2010) B. Glimelius ANNALS OF ONCOLOGY
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
- (2010) K. Potthoff et al. ANNALS OF ONCOLOGY
- Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials
- (2010) K. Bujko et al. ANNALS OF ONCOLOGY
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
- (2010) F. Roila et al. ANNALS OF ONCOLOGY
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- Phase II study of helical tomotherapy for oligometastatic colorectal cancer
- (2010) B. Engels et al. ANNALS OF ONCOLOGY
- Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
- (2010) Gemma Bruera et al. BMC CANCER
- Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
- (2010) R Zarate et al. BRITISH JOURNAL OF CANCER
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up
- (2010) Tae-Won Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study
- (2010) Rong-Xin Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5
- (2010) Sherry L. Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
- (2010) Michael J. O'Connell et al. JOURNAL OF CLINICAL ONCOLOGY
- Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
- (2010) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
- (2010) Jean-Pierre Gérard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study
- (2010) Carlos Fernández-Martos et al. JOURNAL OF CLINICAL ONCOLOGY
- Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
- (2010) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- (2010) Gianluca Masi et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
- (2010) Kei Muro et al. LANCET ONCOLOGY
- Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)
- (2010) Roger von Moos et al. ONKOLOGIE
- Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging
- (2010) Ruud G.P.M. van Stiphout et al. RADIOTHERAPY AND ONCOLOGY
- A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975
- (2009) C. La Vecchia et al. ANNALS OF ONCOLOGY
- Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy
- (2009) Hiroshi Nakano et al. ANNALS OF SURGERY
- The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases
- (2009) Stéphane Benoist et al. ANNALS OF SURGICAL ONCOLOGY
- A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
- (2009) E Vasile et al. BRITISH JOURNAL OF CANCER
- Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study
- (2009) Miriam Koopman et al. EUROPEAN JOURNAL OF CANCER
- Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
- (2009) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
- (2009) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
- (2009) Mark S. Roh et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
- (2009) George A. Poultsides et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study
- (2009) Dominique Elias et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer
- (2009) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer
- (2009) Fang NIE et al. Journal of Digestive Diseases
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- (2009) H. I. Hurwitz et al. ONCOLOGIST
- Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis
- (2009) Xiao Su et al. ONCOLOGY
- Locally Advanced Rectal Cancer: Added Value of Diffusion-weighted MR Imaging in the Evaluation of Tumor Response to Neoadjuvant Chemo- and Radiation Therapy
- (2009) Seung Ho Kim et al. RADIOLOGY
- Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
- (2009) Bernardo L. Rapoport et al. SUPPORTIVE CARE IN CANCER
- Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases
- (2009) Ulf P. Neumann et al. SURGERY
- Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)
- (2008) Lene W. Vestermark et al. ACTA ONCOLOGICA
- Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
- (2008) A. Berglund et al. ANNALS OF ONCOLOGY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
- (2008) M. L. Rothenberg et al. ANNALS OF ONCOLOGY
- Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
- (2008) D. Cunningham et al. ANNALS OF ONCOLOGY
- Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy
- (2008) Hak-Mien Quah et al. DISEASES OF THE COLON & RECTUM
- Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
- (2008) Ludovic Barault et al. INTERNATIONAL JOURNAL OF CANCER
- Preoperative chemoradiationversusradiation alone for stage II and III resectable rectal cancer: A systematic review and meta-analysis
- (2008) Wim Ceelen et al. INTERNATIONAL JOURNAL OF CANCER
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
- (2008) Hansjochen Wilke et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
- (2008) Hendrik-Tobias Arkenau et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials
- (2008) Gunnar Folprecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
- (2008) Emmanuel Mitry et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer
- (2008) Morten Brændengen et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
- (2008) Fairooz F. Kabbinavar et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy for rectal cancer – Authors' reply
- (2008) Richard Gray et al. LANCET
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More